BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $RO.SW readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05646862-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:INAVO121 readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study Evaluating the Efficacy and Safety of Inavolisib Plus F
 ulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With H
 R-Positive\, HER2-Negative\, PIK3CA Mutated\,…\n\nPrimary completion dat
 e: 2026-11-13 (estimated)\nOriginally planned: 2028-05-31 (-18.6 months)\n
 Phase 3 · Oncology · Breast Cancer\nEnrollment: 420 · Sites: 210\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html
 ?nct=NCT05646862\nhttps://clinicaltrials.gov/study/NCT05646862
URL:https://datacutoff.com/radar.html?nct=NCT05646862
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06450639-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261118
DTEND;VALUE=DATE:20261119
SUMMARY:SHIELD DMD readout (P2) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Assess the Efficacy and Safety of Satralizumab in Du
 chenne Muscular Dystrophy (DMD)\n\nPrimary completion date: 2026-11-18 (es
 timated)\nOriginally planned: 2026-06-30 (+4.6 months)\nPhase 2 · Rare ·
  Duchenne Muscular Dystrophy\nEnrollment: 30 · Sites: 18\n\nPrimary compl
 etion = last participant's primary-endpoint data collected\; topline resul
 ts usually follow weeks to months later. Sponsor-reported\, often an estim
 ate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06
 450639\nhttps://clinicaltrials.gov/study/NCT06450639
URL:https://datacutoff.com/radar.html?nct=NCT06450639
CATEGORIES:Rare,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06402838-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261119
DTEND;VALUE=DATE:20261120
SUMMARY:RO7269162 readout (P2) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Evaluate the Safety and Biomarker Effects of RO72691
 62 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Di
 sease (AD)\n\nPrimary completion date: 2026-11-19 (estimated)\nOriginally 
 planned: 2027-05-19 (-5.9 months)\nPhase 2 · Neuro · Alzheimer's Disease
 \nEnrollment: 256 · Sites: 45\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://datacutoff.com/radar.html?nct=NCT06402838\nhttps://clinicaltri
 als.gov/study/NCT06402838
URL:https://datacutoff.com/radar.html?nct=NCT06402838
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03148418-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study in Participants Previously Enrolled in a Genentech- and
 /or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)\n\n
 Primary completion date: 2026-11-30 (estimated)\nOriginally planned: 2027-
 08-05 (-8.1 months)\nPhase 3 · Oncology · Cancer\nEnrollment: 382 · Sit
 es: 170\n\nPrimary completion = last participant's primary-endpoint data c
 ollected\; topline results usually follow weeks to months later. Sponsor-r
 eported\, often an estimate. Not investment advice.\n\nhttps://datacutoff.
 com/radar.html?nct=NCT03148418\nhttps://clinicaltrials.gov/study/NCT031484
 18
URL:https://datacutoff.com/radar.html?nct=NCT03148418
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04302025-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:NAUTIKA1 readout (P2) · Genentech\, Inc. $RO.SW
DESCRIPTION:A Study of Multiple Therapies in Biomarker-selected Participant
 s With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)\n\nPrim
 ary completion date: 2026-11-30 (estimated)\nOriginally planned: 2028-02-0
 2 (-14.1 months)\nPhase 2 · Oncology · Non-small Cell Lung Cancer\nEnrol
 lment: 99 · Sites: 24\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://datacutoff.com/radar.html?nct=NCT04302025\nhttps://clinicaltrials.gov/
 study/NCT04302025
URL:https://datacutoff.com/radar.html?nct=NCT04302025
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05503264-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261216
DTEND;VALUE=DATE:20261217
SUMMARY:Cielo readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Evaluate the Efficacy\, Safety\, Pharmacokinetics (P
 K)\, and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N
 -methyl-D-aspartic Acid Receptor (NMDAR) or A…\n\nPrimary completion dat
 e: 2026-12-16 (estimated)\nOriginally planned: 2025-06-23 (+17.8 months)\n
 Phase 3 · Immuno · NMDAR Autoimmune Encephalitis\, LGI1 Autoimmune Encep
 halitis\nEnrollment: 122 · Sites: 56\n\nPrimary completion = last partici
 pant's primary-endpoint data collected\; topline results usually follow we
 eks to months later. Sponsor-reported\, often an estimate. Not investment 
 advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05503264\nhttps://clin
 icaltrials.gov/study/NCT05503264
URL:https://datacutoff.com/radar.html?nct=NCT05503264
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645692-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab readout (P2) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 Wi
 th or Without TIGIT\, Compared to PD-L1 Alone) in Participants With Untrea
 ted Locally Advanced Metastatic Urothelial …\n\nPrimary completion date:
  2026-12-31 (estimated)\nPhase 2 · Oncology · Urothelial Cancer\nEnrollm
 ent: 204 · Sites: 56\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://datacutoff.com/radar.html?nct=NCT05645692\nhttps://clinicaltrials.gov/s
 tudy/NCT05645692
URL:https://datacutoff.com/radar.html?nct=NCT05645692
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910528-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TAHOE readout (P2) · Hoffmann-La Roche $RO.SW
DESCRIPTION:Afimkibart (RO7790121) for the Treatment of Moderate to Severe 
 Active Crohn's Disease\n\nPrimary completion date: 2026-12-31 (estimated)\
 nOriginally planned: 2024-12-01 (+25.0 months)\nPhase 2 · GI·Renal·Heme
  · Crohns Disease\nEnrollment: 21 · Sites: 11\n\nPrimary completion = la
 st participant's primary-endpoint data collected\; topline results usually
  follow weeks to months later. Sponsor-reported\, often an estimate. Not i
 nvestment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05910528\nht
 tps://clinicaltrials.gov/study/NCT05910528
URL:https://datacutoff.com/radar.html?nct=NCT05910528
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05170204-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:HORIZON 1 readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study Evaluating the Efficacy and Safety of Multiple Therapie
 s in Cohorts of Participants With Locally Advanced\, Unresectable\, Stage 
 III Non-Small Cell Lung Cancer (NSCLC)\n\nPrimary completion date: 2027-01
 -19 (estimated)\nOriginally planned: 2029-06-17 (-28.9 months)\nPhase 3 ·
  Oncology · Non-Small Cell Lung Cancer\nEnrollment: 68 · Sites: 45\n\nPr
 imary completion = last participant's primary-endpoint data collected\; to
 pline results usually follow weeks to months later. Sponsor-reported\, oft
 en an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.htm
 l?nct=NCT05170204\nhttps://clinicaltrials.gov/study/NCT05170204
URL:https://datacutoff.com/radar.html?nct=NCT05170204
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589986-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Ametrine-1 readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Assess the Efficacy and Safety of Afimkibart (Also K
 nown as RO7790121) for Induction and Maintenance Therapy in Participants W
 ith Moderately to Severely Active Ulcerati…\n\nPrimary completion date: 
 2027-01-30 (estimated)\nOriginally planned: 2027-06-30 (-5.0 months)\nPhas
 e 3 · GI·Renal·Heme · Moderately to Severely Active Ulcerative Colitis
 \nEnrollment: 400 · Sites: 184\n\nPrimary completion = last participant's
  primary-endpoint data collected\; topline results usually follow weeks to
  months later. Sponsor-reported\, often an estimate. Not investment advice
 .\n\nhttps://datacutoff.com/radar.html?nct=NCT06589986\nhttps://clinicaltr
 ials.gov/study/NCT06589986
URL:https://datacutoff.com/radar.html?nct=NCT06589986
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04657289-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:Ranibizumab readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study of the Efficacy\, Safety\, and Pharmacokinetics of a 36
 -Week Refill Regimen for the Port Delivery System With Ranibizumab in Pati
 ents With Neovascular Age-Related Macular De…\n\nPrimary completion date
 : 2027-02-04 (estimated)\nOriginally planned: 2023-09-21 (+40.5 months)\nP
 hase 3 · Eye · Neovascular Age-related Macular Degeneration (nAMD)\nEnro
 llment: 451 · Sites: 104\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://datacutoff.com/radar.html?nct=NCT04657289\nhttps://clinicaltrials.g
 ov/study/NCT04657289
URL:https://datacutoff.com/radar.html?nct=NCT04657289
CATEGORIES:Eye,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02320435-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270328
DTEND;VALUE=DATE:20270329
SUMMARY:Pertuzumab readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Safety and Efficacy Extension Study of Pertuzumab in Patients
  With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pe
 rtuzumab Clinical Trial\n\nPrimary completion date: 2027-03-28 (estimated)
 \nOriginally planned: 2025-01 (+26.8 months)\nPhase 3 · Oncology · Solid
  Tumors\nEnrollment: 154 · Sites: 62\n\nPrimary completion = last partici
 pant's primary-endpoint data collected\; topline results usually follow we
 eks to months later. Sponsor-reported\, often an estimate. Not investment 
 advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT02320435\nhttps://clin
 icaltrials.gov/study/NCT02320435
URL:https://datacutoff.com/radar.html?nct=NCT02320435
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04873362-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Astefania readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study Evaluating the Efficacy and Safety of Adjuvant Atezoliz
 umab or Placebo and Trastuzumab Emtansine for Participants With HER2-Posit
 ive Breast Cancer at High Risk of Recurren…\n\nPrimary completion date: 
 2027-03-31 (estimated)\nOriginally planned: 2025-12-18 (+15.4 months)\nPha
 se 3 · Oncology · Breast Cancer\nEnrollment: 1188 · Sites: 238\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?n
 ct=NCT04873362\nhttps://clinicaltrials.gov/study/NCT04873362
URL:https://datacutoff.com/radar.html?nct=NCT04873362
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05199688-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:SAkuraSun readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Evaluate Pharmacokinetics\, Efficacy\, Safety\, Tole
 rability\, and Pharmacodynamics of Satralizumab in Pediatric Patients With
  Aquaporin-4 Antibody Positive Neuromyelitis O…\n\nPrimary completion da
 te: 2027-03-31 (estimated)\nOriginally planned: 2024-07-29 (+32.0 months)\
 nPhase 3 · Neuro · Neuromyelitis Optica Spectrum Disorder\, NMOSD\nEnrol
 lment: 8 · Sites: 14\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://datacutoff.com/radar.html?nct=NCT05199688\nhttps://clinicaltrials.gov/s
 tudy/NCT05199688
URL:https://datacutoff.com/radar.html?nct=NCT05199688
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07137598-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270417
DTEND;VALUE=DATE:20270418
SUMMARY:Afimkibart readout (P2) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Assess the Efficacy and Safety of RO7790121 in Parti
 cipants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responde
 d to or Who Cannot Tolerate Tumor Necrosis…\n\nPrimary completion date: 
 2027-04-17 (estimated)\nOriginally planned: 2027-07-09 (-2.7 months)\nPhas
 e 2 · Immuno · Rheumatoid Arthritis\nEnrollment: 160 · Sites: 66\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html
 ?nct=NCT07137598\nhttps://clinicaltrials.gov/study/NCT07137598
URL:https://datacutoff.com/radar.html?nct=NCT07137598
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04432584-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270418
DTEND;VALUE=DATE:20270419
SUMMARY:COMMODORE 1 readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study Evaluating the Safety\, Pharmacokinetics\, and Efficacy
  of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal
  Hemoglobinuria (PNH) Currently Treated With…\n\nPrimary completion date
 : 2027-04-18 (estimated)\nOriginally planned: 2021-07-08 (+69.3 months)\nP
 hase 3 · GI·Renal·Heme · Paroxysmal Nocturnal Hemoglobinuria\nEnrollme
 nt: 190 · Sites: 80\n\nPrimary completion = last participant's primary-en
 dpoint data collected\; topline results usually follow weeks to months lat
 er. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:
 //datacutoff.com/radar.html?nct=NCT04432584\nhttps://clinicaltrials.gov/st
 udy/NCT04432584
URL:https://datacutoff.com/radar.html?nct=NCT04432584
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827599-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pearlstone readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Confirm Efficacy of a Single Dose of Baloxavir Marbo
 xil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in
  Chinese Participants\n\nPrimary completion date: 2027-04-30 (estimated)\n
 Phase 3 · Infectious · Influenza\, Human\, Respiratory Tract Infections\
 , Post-exposure Prophylaxis\nEnrollment: 325 · Sites: 20\n\nPrimary compl
 etion = last participant's primary-endpoint data collected\; topline resul
 ts usually follow weeks to months later. Sponsor-reported\, often an estim
 ate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07
 827599\nhttps://clinicaltrials.gov/study/NCT07827599
URL:https://datacutoff.com/radar.html?nct=NCT07827599
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05894239-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:INAVO122 readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Inavolisib in Co
 mbination With Phesgo Versus Placebo in Combination With Phesgo in Partici
 pants With PIK3CA-Mutated HER2-Positive Lo…\n\nPrimary completion date: 
 2027-05-03 (estimated)\nOriginally planned: 2028-10-31 (-18.0 months)\nPha
 se 3 · Oncology · Metastatic Breast Cancer\nEnrollment: 230 · Sites: 19
 2\n\nPrimary completion = last participant's primary-endpoint data collect
 ed\; topline results usually follow weeks to months later. Sponsor-reporte
 d\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/ra
 dar.html?nct=NCT05894239\nhttps://clinicaltrials.gov/study/NCT05894239
URL:https://datacutoff.com/radar.html?nct=NCT05894239
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06094010-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270511
DTEND;VALUE=DATE:20270512
SUMMARY:Pebblestone readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Surveillance Study of Susceptibility to Baloxavir Marboxil in
  Pediatric Participants With Influenza and Transmission of Influenza to Ho
 usehold Contacts\n\nPrimary completion date: 2027-05-11 (estimated)\nPhase
  3 · Infectious · Influenza\nEnrollment: 1100 · Sites: 52\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NC
 T06094010\nhttps://clinicaltrials.gov/study/NCT06094010
URL:https://datacutoff.com/radar.html?nct=NCT06094010
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07161258-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:FENerations1 readout (P2) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Pharmacokinetics (PK)\, Pharmacodynamics (PD)\, Safety and To
 lerability Study of Fenebrutinib in Children and Adolescents With Relapsin
 g Multiple Sclerosis (RMS)\n\nPrimary completion date: 2027-06-08 (estimat
 ed)\nPhase 2 · Neuro · Relapsing Multiple Sclerosis\nEnrollment: 12 · S
 ites: 17\n\nPrimary completion = last participant's primary-endpoint data 
 collected\; topline results usually follow weeks to months later. Sponsor-
 reported\, often an estimate. Not investment advice.\n\nhttps://datacutoff
 .com/radar.html?nct=NCT07161258\nhttps://clinicaltrials.gov/study/NCT07161
 258
URL:https://datacutoff.com/radar.html?nct=NCT07161258
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00781612-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Docetaxel readout (P2) · Genentech\, Inc. $RO.SW
DESCRIPTION:A Safety Extension Study of Trastuzumab Emtansine in Participan
 ts Previously Treated With Trastuzumab Emtansine Alone or in Combination W
 ith Other Anti-Cancer Therapy in One of th…\n\nPrimary completion date: 
 2027-06-30 (estimated)\nOriginally planned: 2011-09 (+189.9 months)\nPhase
  2 · Oncology · Neoplasm Metastasis\nEnrollment: 378 · Sites: 179\n\nPr
 imary completion = last participant's primary-endpoint data collected\; to
 pline results usually follow weeks to months later. Sponsor-reported\, oft
 en an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.htm
 l?nct=NCT00781612\nhttps://clinicaltrials.gov/study/NCT00781612
URL:https://datacutoff.com/radar.html?nct=NCT00781612
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:B-FAST readout (P2/3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Multiple Targete
 d Therapies as Treatments for Participants With Non-Small Cell Lung Cancer
  (NSCLC)\n\nPrimary completion date: 2027-06-30 (estimated)\nOriginally pl
 anned: 2020-03-03 (+87.9 months)\nPhase 2/3 · Oncology · Non-Small Cell 
 Lung Cancer\nEnrollment: 1000 · Sites: 161\n\nPrimary completion = last p
 articipant's primary-endpoint data collected\; topline results usually fol
 low weeks to months later. Sponsor-reported\, often an estimate. Not inves
 tment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT03178552\nhttps:
 //clinicaltrials.gov/study/NCT03178552
URL:https://datacutoff.com/radar.html?nct=NCT03178552
CATEGORIES:Oncology,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112965-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:An Extension Study in Participants Previously Enrolled in a Gen
 entech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbre
 lla C)\n\nPrimary completion date: 2027-06-30 (estimated)\nOriginally plan
 ned: 2025-11-21 (+19.3 months)\nPhase 3 · Oncology · Neoplasms\nEnrollme
 nt: 49 · Sites: 17\n\nPrimary completion = last participant's primary-end
 point data collected\; topline results usually follow weeks to months late
 r. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:/
 /datacutoff.com/radar.html?nct=NCT05112965\nhttps://clinicaltrials.gov/stu
 dy/NCT05112965
URL:https://datacutoff.com/radar.html?nct=NCT05112965
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05562947-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HUTONG readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study of the Efficacy\, Safety\, and Pharmacokinetics (PK) of
  the Port Delivery System With Ranibizumab (PDS) in Chinese Participants W
 ith Neovascular Age-related Macular Degenera…\n\nPrimary completion date
 : 2027-06-30 (estimated)\nOriginally planned: 2027-02-28 (+4.0 months)\nPh
 ase 3 · Eye · Neovascular Age-related Macular Degeneration\, nAMD\nEnrol
 lment: 68 · Sites: 14\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://datacutoff.com/radar.html?nct=NCT05562947\nhttps://clinicaltrials.gov/
 study/NCT05562947
URL:https://datacutoff.com/radar.html?nct=NCT05562947
CATEGORIES:Eye,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05878769-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Astegolimab readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Evaluate the Long-Term Safety of Astegolimab in Part
 icipants With Chronic Obstructive Pulmonary Disease (COPD)\n\nPrimary comp
 letion date: 2027-06-30 (estimated)\nPhase 3 · Respiratory · Chronic Obs
 tructive Pulmonary Disease\nEnrollment: 2000 · Sites: 480\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0
 5878769\nhttps://clinicaltrials.gov/study/NCT05878769
URL:https://datacutoff.com/radar.html?nct=NCT05878769
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04108156-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270720
DTEND;VALUE=DATE:20270721
SUMMARY:Pagoda readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Evaluate Efficacy\, Safety & Pharmacokinetics of the
  Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic
  Macular Edema (DME) Compared With Intravit…\n\nPrimary completion date:
  2027-07-20 (estimated)\nOriginally planned: 2021-10-31 (+68.6 months)\nPh
 ase 3 · Cardio-Met · Diabetic Macular Edema\nEnrollment: 672 · Sites: 8
 9\n\nPrimary completion = last participant's primary-endpoint data collect
 ed\; topline results usually follow weeks to months later. Sponsor-reporte
 d\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/ra
 dar.html?nct=NCT04108156\nhttps://clinicaltrials.gov/study/NCT04108156
URL:https://datacutoff.com/radar.html?nct=NCT04108156
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096779-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Kirros readout (P2) · Genentech\, Inc. $RO.SW
DESCRIPTION:A Study Evaluating Atezolizumab\, With or Without Bevacizumab\,
  in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh
  B7 and B8 Cirrhosis\n\nPrimary completion date: 2027-07-30 (estimated)\nO
 riginally planned: 2026-05-02 (+14.9 months)\nPhase 2 · Oncology · Hepat
 ocellular Carcinoma\nEnrollment: 30 · Sites: 54\n\nPrimary completion = l
 ast participant's primary-endpoint data collected\; topline results usuall
 y follow weeks to months later. Sponsor-reported\, often an estimate. Not 
 investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06096779\nh
 ttps://clinicaltrials.gov/study/NCT06096779
URL:https://datacutoff.com/radar.html?nct=NCT06096779
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054190-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Inavolisib readout (P2) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Test Inavolisib Treatments in Participants With Earl
 y-Stage\, PIK3CA-Mutated Breast Cancer\n\nPrimary completion date: 2027-07
 -31 (estimated)\nOriginally planned: 2027-02-27 (+5.1 months)\nPhase 2 · 
 Oncology · Breast Cancer\nEnrollment: 120 · Sites: 37\n\nPrimary complet
 ion = last participant's primary-endpoint data collected\; topline results
  usually follow weeks to months later. Sponsor-reported\, often an estimat
 e. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0705
 4190\nhttps://clinicaltrials.gov/study/NCT07054190
URL:https://datacutoff.com/radar.html?nct=NCT07054190
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979336-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:RO7837195 readout (P2) · Genentech\, Inc. $RO.SW
DESCRIPTION:A Study to Evaluate the Efficacy\, Safety\, and Pharmacokinetic
 s (PK) of RO7837195 in Participants With Moderately to Severely Active Ulc
 erative Colitis (UC)\n\nPrimary completion date: 2027-08-25 (estimated)\nP
 hase 2 · GI·Renal·Heme · Ulcerative Colitis\nEnrollment: 224 · Sites:
  111\n\nPrimary completion = last participant's primary-endpoint data coll
 ected\; topline results usually follow weeks to months later. Sponsor-repo
 rted\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com
 /radar.html?nct=NCT06979336\nhttps://clinicaltrials.gov/study/NCT06979336
URL:https://datacutoff.com/radar.html?nct=NCT06979336
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084936-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:GLOBRYTE readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Evaluate Glofitamab as a Single Agent vs. Investigat
 or's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma\
 n\nPrimary completion date: 2027-08-31 (estimated)\nOriginally planned: 20
 26-02-02 (+18.9 months)\nPhase 3 · Oncology · Lymphoma\nEnrollment: 182 
 · Sites: 83\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://datacu
 toff.com/radar.html?nct=NCT06084936\nhttps://clinicaltrials.gov/study/NCT0
 6084936
URL:https://datacutoff.com/radar.html?nct=NCT06084936
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416526-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:ZEBRHA 1 readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Clinical Study to Evaluate the Effects of NXT007 Compared to 
 Factor VIII Prophylaxis in Participants With Hemophilia A\n\nPrimary compl
 etion date: 2027-09-23 (estimated)\nPhase 3 · Rare · Hemophilia A\nEnrol
 lment: 138 · Sites: 36\n\nPrimary completion = last participant's primary
 -endpoint data collected\; topline results usually follow weeks to months 
 later. Sponsor-reported\, often an estimate. Not investment advice.\n\nhtt
 ps://datacutoff.com/radar.html?nct=NCT07416526\nhttps://clinicaltrials.gov
 /study/NCT07416526
URL:https://datacutoff.com/radar.html?nct=NCT07416526
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05207670-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:MorningSun readout (P2) · Genentech\, Inc. $RO.SW
DESCRIPTION:A Study Evaluating the Safety\, Efficacy\, and Pharmacokinetics
  of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignanc
 ies\n\nPrimary completion date: 2027-10-01 (estimated)\nOriginally planned
 : 2026-12-17 (+9.5 months)\nPhase 2 · Oncology · Non-Hodgkin Lymphoma\nE
 nrollment: 320 · Sites: 39\n\nPrimary completion = last participant's pri
 mary-endpoint data collected\; topline results usually follow weeks to mon
 ths later. Sponsor-reported\, often an estimate. Not investment advice.\n\
 nhttps://datacutoff.com/radar.html?nct=NCT05207670\nhttps://clinicaltrials
 .gov/study/NCT05207670
URL:https://datacutoff.com/radar.html?nct=NCT05207670
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047080-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Glofitamab readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:An Open-Label Study Comparing Glofitamab and Polatuzumab Vedoti
 n + Rituximab\, Cyclophosphamide\, Doxorubicin\, and Prednisone Versus Pol
 a-R-CHP in Previously Untreated Patients With…\n\nPrimary completion dat
 e: 2027-10-01 (estimated)\nOriginally planned: 2026-06-01 (+16.0 months)\n
 Phase 3 · Oncology · Large B-Cell Lymphoma\nEnrollment: 1130 · Sites: 2
 29\n\nPrimary completion = last participant's primary-endpoint data collec
 ted\; topline results usually follow weeks to months later. Sponsor-report
 ed\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/r
 adar.html?nct=NCT06047080\nhttps://clinicaltrials.gov/study/NCT06047080
URL:https://datacutoff.com/radar.html?nct=NCT06047080
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998524-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271006
DTEND;VALUE=DATE:20271007
SUMMARY:WILL-EMI readout (P3) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Assess the Efficacy and Safety of Emicizumab in Part
 icipants With Type 3 Von Willebrand Disease\n\nPrimary completion date: 20
 27-10-06 (estimated)\nOriginally planned: 2027-12-15 (-2.3 months)\nPhase 
 3 · Rare · Von Willebrand Disease\, Type 3\nEnrollment: 75 · Sites: 30\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://datacutoff.com/rada
 r.html?nct=NCT06998524\nhttps://clinicaltrials.gov/study/NCT06998524
URL:https://datacutoff.com/radar.html?nct=NCT06998524
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06534983-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:IMCODE004 readout (P2) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Autogene Cevumer
 an With Nivolumab Versus Nivolumab Alone in Participants With High-risk Mu
 scle-invasive Urothelial Carcinoma (MIUC)\n\nPrimary completion date: 2027
 -11-10 (estimated)\nOriginally planned: 2028-11-06 (-11.9 months)\nPhase 2
  · Oncology · Muscle-invasive Urothelial Carcinoma\nEnrollment: 62 · Si
 tes: 38\n\nPrimary completion = last participant's primary-endpoint data c
 ollected\; topline results usually follow weeks to months later. Sponsor-r
 eported\, often an estimate. Not investment advice.\n\nhttps://datacutoff.
 com/radar.html?nct=NCT06534983\nhttps://clinicaltrials.gov/study/NCT065349
 83
URL:https://datacutoff.com/radar.html?nct=NCT06534983
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589686-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:ZYNERGY readout (P2) · Hoffmann-La Roche $RO.SW
DESCRIPTION:A Dose-Finding Study of Petrelintide With Enicepatide (RO779506
 8) in Adults With Obesity or Overweight\n\nPrimary completion date: 2027-1
 1-12 (estimated)\nPhase 2 · Cardio-Met · Obesity or Overweight\nEnrollme
 nt: 486 · Sites: 0\n\nPrimary completion = last participant's primary-end
 point data collected\; topline results usually follow weeks to months late
 r. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:/
 /datacutoff.com/radar.html?nct=NCT07589686\nhttps://clinicaltrials.gov/stu
 dy/NCT07589686
URL:https://datacutoff.com/radar.html?nct=NCT07589686
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
